Embryonal rhabdomyosarcoma
Drug research and approvals for embryonal rhabdomyosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 23 studies of embryonal rhabdomyosarcoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 23
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid TumorsNCT07628634 · Early Phase 1 · University of California, Irvine · starts May 1, 2026
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic…NCT07584499 · Phase 1 · Sun Yat-sen University · starts May 30, 2026
- Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)NCT07172958 · Phase 1 · Children's National Research Institute · starts Jan 27, 2026
- Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific…NCT07148050 · Phase 1 · Seattle Children's Hospital · starts Dec 22, 2025
- PEEL-224, Vincristine and Temozolomide in Pediatric Solid TumorsNCT06721689 · Phase 1 / Phase 2 · Theodore Laetsch · starts Mar 23, 2025
- Ivonescimab in the Treatment of Multiple Advanced TumorsNCT06683846 · Phase 2 · Fudan University · starts Nov 20, 2024
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsNCT06625190 · Phase 1 / Phase 2 · University of Florida · starts Feb 11, 2026
- Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsNCT06541262 · Phase 1 / Phase 2 · Milton S. Hershey Medical Center · starts Oct 30, 2024
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric…NCT06441331 · Phase 1 · ITM Solucin GmbH · starts Sep 26, 2025
Phase 3 6
- DactinomycinDNA inhibitor
- CyclophosphamideDNA inhibitor
- VincristineTubulin inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- VinorelbineTubulin inhibitor
- TemsirolimusFK506-binding protein 1A inhibitor
Phase 2 4
- DoxorubicinDNA topoisomerase II alpha inhibitor
- IfosfamideDNA inhibitor
- TemozolomideDNA inhibitor
- CixutumumabInsulin-like growth factor I receptor antagonist
How its trials ended
37 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 7 whose ending is known, 29% met their primary endpoint, 43% missed it and 29% stopped early.
- Completed, result not reported2362%
- Ongoing719%
- Missed its primary endpoint38%
- Met its primary endpoint25%
- Stopped: sponsor or business decision13%
- Stopped: other or unclear13%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA